Skip to main navigation

Japanese site

Overview
News
Events & Presentations
- Events
- Presentations
Stock
Financials
- SEC Filings
- Annual Reports
Governance
- Documents & Charters
Resources
- Email Alerts
- Contact Us
Corporate Home

News Releases

Search

News Category

Year

September 8, 2026

MediciNova to Participate in Two Investor Conferences in September

July 15, 2026

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

June 30, 2026

MediciNova CEO Provides Shareholder Update

June 8, 2026

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

May 26, 2026

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

April 27, 2026

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

March 16, 2026

MediciNova to Participate at the 38th Annual ROTH Conference

January 29, 2026

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

January 6, 2026

2026 New Year’s Greetings from the CEO

Investor Contact

MediciNova, Inc.
David H. Crean, Ph.D.
Chief Business Officer

drafts info@medicinova.com

Subscribe to our Email Alerts

Email Address Required

© 2026 MediciNova, Inc.

|

Terms of Use
Privacy Policy

Search Investors

Search this site